Skip to content
Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to improve treatment outcomes for children and adults with cancer
Clarity Pharmaceuticals - Radiopharmaceutical Therapies and ImagingClarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Discovery Program
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Discovery Program
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube

Daily Archives: July 30, 2019

Robert Vickery Appointed Chief Financial Officer

News, Press ReleasesBy Lisa SadetskayaJuly 30, 2019

Sydney, Australia 30 July 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Robert Vickery as Chief Financial Officer. Robert is a transaction and change focused finance executive with over 30 years of experience and extensive involvement in life sciences and early stage…

Go to Top